Conference Details - Agenda
View all Conferences
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
Seventh International Colorectal Cancer Congress
The Fairmont Turnberry Isle
Aventura, FL
October 16-18, 2008
| 1:30 pm |
Registration
|
| 2:00 pm |
Welcome and Introductions
Edward Chu |
| 2:05 pm |
Presession Survey
|
| 2:10 pm |
Optimizing Chemotherapy for Newly Diagnosed Metastatic Disease
Richard Goldberg |
| 2:35 pm |
Question-and-Answer Session
|
| 2:40 pm |
Oral Fluoropyrimidine-Based Regimens
Jean-Yves Douillard |
| 3:05 pm |
Question-and-Answer Session
|
| 3:10 pm |
What Have We Learned About Managing Neurotoxicity?
Axel Grothey |
| 3:35 pm |
Roundtable Discussion: Should There Be Planned Chemotherapy Holidays?
Panel Discussion: Edward Chu, Jean-Yves Douillard, Richard Goldberg, Axel Grothey |
| 4:15 pm |
Overview of Adjuvant Therapy Options
Daniel G. Haller |
| 4:40 pm |
Question-and-Answer Session
|
| 4:45 pm |
Molecular Profiling in Early-Stage Colorectal Cancer
Daniel G. Haller, MD |
| 5:10 pm |
Question-and-Answer Session
|
| 5:15 pm |
Safety of Anti-VEGF Antibody in Adjuvant Therapy for Colon Cancer: Initial Results of the NSABP C-08 Trial
Richard Goldberg, MD |
| 5:40 pm |
Question-and-Answer Session
|
| 5:45 pm |
Clinical Vignettes of Patients With Early-Stage Colorectal Cancer: Case-Based Discussion
Panel Discussion: Edward Chu, Richard Goldberg, Aimery de Gramont, Daniel G. Haller |
| 6:25 pm |
Postsession Survey
|
| 6:30 pm |
Adjourn
|
| 7:30 am |
Continental Breakfast and Registration
|
| 7:55 am |
Presession Survey
|
| 8:00 am |
Current Clinical Data on Fully Human Anti-EGFR Antibody
J. Randolph Hecht |
| 8:25 am |
Question-and-Answer Session
|
| 8:30 am |
Clinical Trials of Chimeric Anti-EGFR Antibody
Howard Hochster |
| 8:55 am |
Question-and-Answer Session
|
| 9:00 am |
Key to Patient Selection for EGFR-Targeted Therapy: Understanding KRAS
Panel Discussion: Edward Chu, Axel Grothey, J. Randolph Hecht, Howard Hochster |
| 9:45 am |
Break
|
| 10:00 am |
Should Anti-VEGF Therapy Continue Beyond Progression? Data From the BRiTE Trial
Axel Grothey |
| 10:25 am |
Question-and-Answer Session
|
| 10:30 am |
Role of VEGFR Tyrosine Kinase Inhibitors in Colorectal Cancer
Alex Adjei |
| 10:55 am |
Question-and-Answer Session
|
| 11:00 am |
Managing Adverse Events Associated With Antiangiogenic Therapy
Cathy Eng |
| 11:25 am |
Question-and-Answer Session
|
| 11:30 am |
Resistance to Anti-VEGF Therapies
Lee M. Ellis |
| 11:55 am |
Question-and-Answer Session
|
| 12:00 pm |
Dual Biologics in First-line Metastatic Disease
Al B. Benson III |
| 12:25 pm |
Question-and-Answer Session
|
| 12:30 pm |
Postsession Survey
|
| 12:35 pm |
Lunch
|
| 1:30 pm |
Anti-EGFR Plus Chemotherapy
John Marshall |
| 1:45 pm |
Anti-VEGF Plus Chemotherapy
Aimery de Gramont |
| 2:00 pm |
Rebuttals
|
| 2:10 pm |
Question-and-Answer Session
|
| 2:15 pm |
Highlights From International Congresses
Udo Vanhoefer |
| 2:45 pm |
European Compared to North American Treatment Strategies
Panel Discussion: Aimery de Gramont, Jean-Yves Douillard, Daniel G. Haller, Richard Goldberg, Axel Grothey, Udo Vanhoefer |
| 4:00 pm |
Adjourn
|
| 4:30 pm |
Anti–IGF-1R Antibodies
M. Wasif Saif |
| 4:50 pm |
Chemoresistance and Molecular Targets
Lee M. Ellis |
| 5:10 pm |
HGF-Directed Therapy
Cathy Eng |
| 5:30 pm |
TBA
John J. Wright |
| 5:50 pm |
CPX-1
Gerald Batist |
| 6:10 pm |
Panel Discussion
|
| 7:30 am |
Continental Breakfast and Registration
|
| 8:00 am |
Proteomic Approaches to Gene Expression Profiling and Biomarker Analysis
Emanuel Petricoin |
| 8:20 am |
Question-and-Answer Session
|
| 8:25 am |
Predictive Biomarkers of Response or Toxicity
Heinz-Josef Lenz |
| 8:45 am |
Question-and-Answer Session
|
| 8:50 am |
Pharmacogenomic Profiling
Richard Goldberg |
| 9:10 am |
Question-and-Answer Session
|
| 9:15 am |
Role of 5-FU Drug Monitoring
Wasif Saif |
| 9:35 am |
Question-and-Answer Session
|
| 9:40 am |
Break
|
| 9:55 am |
Presession Survey
|
| 10:00 am |
Perioperative Systemic Therapy for Resectable Colorectal Liver Metastasis: Where Do We Go From Here?
Steven Curley |
| 10:25 am |
Question-and-Answer Session
|
| 10:30 am |
Neoadjuvant Therapy Options and Duration: To Best Response or Resectability?
Axel Grothey |
| 10:55 am |
Question-and-Answer Session
|
| 11:00 am |
Controversial Cases in Managing Patients With Liver Metastases
Panel Discussion: Steven Curley, Axel Grothey |
| 11:25 am |
Postsession Survey
|
| 11:30 am |
Lunch
|
| 12:30 pm |
Presession Survey
|
| 12:35 pm |
Advances in Surgical Techniques
Charles Cha |
| 1:00 pm |
Question-and-Answer Session
|
| 1:05 pm |
Initial Management of uT3 Rectal Cancer: Neoadjuvant Therapy
Bruce Minsky |
| 1:20 pm |
Initial Management of uT3 Rectal Cancer: Surgery
Charles Cha |
| 1:35 pm |
Rebuttals
|
| 1:45 pm |
Question-and-Answer Session
|
| 1:55 pm |
Anti-VEGF Biologic Therapy for Rectal Cancer
Christopher Willett |
| 2:20 pm |
Question-and-Answer Session
|
| 2:25 pm |
What Is the Ideal Chemotherapy for Use in Neoadjuvant Chemoradiation Therapy for Rectal Cancer?
Cathy Eng |
| 2:50 pm |
Question-and-Answer Session
|
| 2:55 pm |
Is There Still a Role for Postoperative Adjuvant Chemotherapy Following Neoadjuvant Chemoradiation Therapy for Rectal Cancer?
Panel Discussion: Charles Cha, Cathy Eng, Bruce Minsky, Christopher Willett |
| 3:20 pm |
Question-and-Answer Session
|
| 3:25 pm |
Postsession Survey
|
| 3:30 pm |
Closing Remarks/Adjourn
Edward Chu |
